In vivo, tRF‐22 overexpression resulted in tumor growth accompanied by an increase in PMN‐MDSCs and a decrease in CD8+ T cells, while these effects were mitigated by silencing HNRNPAB or TGFB2, or by applying anti‐TGFβ antibody (Figure 5F–I; Figure S13H, Supporting Information). Here, TGFB1 is linked to neoplasm.